The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Early and protective microglial activation in Alzheimer’s disease: a prospective study using18F-DPA-714 PET imaging
Open accessAbstract
While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer's disease, the impact of the microglia response in Alzheimer's disease remains a matter of debate. We aimed to study microglial activation in early Alzheimer's disease and its impact on clinical progression using a second-generation 18-kDa translocator protein positron emission tomography radiotracer together with amyloid imaging using Pittsburgh compound B positron emission tomography. We enrolled 96 subjects, 64 patients with Alzheimer's disease and 32 controls, from the IMABio3 study, who had both (11)C-Pittsburgh compound B and (18)F-DPA-714 positron emission tomography imaging. Patients with Alzheimer's disease were classified as prodromal Alzheimer's disease (n = 38) and Alzheimer's disease dementia (n = 26). Translocator protein-binding was measured using a simple ratio method with cerebellar grey matter as reference tissue, taking into account regional atrophy. Images were analysed at the regional (volume of interest) and at the voxel level. Translocator protein genotyping allowed the classification of all subjects in high, mixed and low affinity binders. Thirty high+mixed affinity binders patients with Alzheimer's disease were dichotomized into slow decliners (n = 10) or fast decliners (n = 20) after 2 years of follow-up. All patients with Alzheimer's disease had an amyloid positive Pittsburgh compound B positron emission tomography. Among controls, eight had positive amyloid scans (n = 6 high+mixed affinity binders), defined as amyloidosis controls, and were analysed separately. By both volumes of interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity binders, mixed affinity binders and high+mixed affinity binders Alzheimer's disease groups compared to controls, especially at the prodromal stage, involving the temporo-parietal cortex. Translocator protein-binding was positively correlated with Mini-Mental State Examination scores and grey matter volume, as well as with Pittsburgh compound B binding. Amyloidosis controls displayed higher translocator protein-binding than controls, especially in the frontal cortex. We found higher translocator protein-binding in slow decliners than fast decliners, with no difference in Pittsburgh compound B binding. Microglial activation appears at the prodromal and possibly at the preclinical stage of Alzheimer's disease, and seems to play a protective role in the clinical progression of the disease at these early stages. The extent of microglial activation appears to differ between patients, and could explain the overlap in translocator protein binding values between patients with Alzheimer's disease and amyloidosis controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ itself acts as a proinflammatory agent, activating many inflammatory components.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the early stages of AD, initial microglial activation may serve a protective role (anti-neuroinflammatory), whereby it tries to clear the amyloid and release nerve growth factors. However, when Aβ or other toxic products over-accumulate, proinflammatory phenotypes are activated, which damage the neurons [26].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the brains of patients with AD exhibited evidence of sustained inflammation.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[18F]DPA-714 was extensively studied in preclinical and clinical models [58–61], as a biomarker of neuroinflammation in various human CNS disorders [58].”
From Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression (2022) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, early neuroinflammation has been shown to be an adaptive mechanism by microglia that protects against AD pathology by reducing the levels of Aβ and tau.118–120”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [120]
In the citing paper
“In vivo imaging shows that microglia activation precedes the onset of AD (100) and is paralleled by increased levels of inflammatory markers in the cerebrospinal fluid (101)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“in MCI, microglial activation was positively correlated with cognition and gray matter volume, suggesting that microglial activation plays a protective role in the early phase of clinically apparent disease (100).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“Of relevance, PET studies have indicated increased microglia activation in the precuneus and parietal cortex in AD.47,48”
From CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) · cites this paper as [48]
In the citing paper
“Another study that divided AD subjects into fast decliners and slow decliners measured a higher TSPO signal in the brains of slow decliners, consistent with a protective role for microglial activation even in stages of AD when dementia is evident (Hamelin et al., 2016).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Hamelin et al., 2016
In the citing paper
“This is consistent with the finding that early microglial activation in response to amyloid plaques, as assessed by in vivo microglial imaging studies, is correlated with increased grey matter volume and reduced rate of cognitive decline46,47.”
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Conversion of amyloid positive and negative MCI to AD over 3 years
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 537
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 536
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 522
Imaging Neuroinflammation in Neurodegenerative Disorders
Masdeu, J. C., Pascual, B., & Fujita, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263200 · Cited by 77
PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias
Zhang, X. Y., Yang, Z. L., Lu, G., Yang, G. F., & Zhang, L. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00343 · Cited by 75
James, M. L., Belichenko, N. P., Shuhendler, A. J., Höhne, A., Andrews, L., Condon, C., Nguyen, T. V., Reiser, V., Jones, P. A., Trigg, W., et al. (2017) · Theranostics · doi:10.7150/thno.17666 · Cited by 77
In vivo PET imaging of neuroinflammation in Alzheimer’s disease
Lagarde, J., Sarazin, M., & Bottlaender, M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1731-x · Cited by 79
Self-citationFrederiksen, H. R., Haukedal, H., & Freude, K. (2019) · BioMed Research International · doi:10.1155/2019/7420189 · Cited by 63
Imaging and Molecular Mechanisms of Alzheimer’s Disease: A Review
Femminella, G. D., Thayanandan, T., Calsolaro, V., Komici, K., Rengo, G., Corbi, G., & Ferrara, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123702 · Cited by 74
Ismail, R., Hansen, A. K., Parbo, P., Brændgaard, H., Gottrup, H., Brooks, D. J., & Borghammer, P. (2018) · International Journal of Alzheimer s Disease · doi:10.1155/2018/6852303 · Cited by 71
Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update
Gouilly, D., Saint‐Aubert, L., Ribeiro, M. J., Salabert, A., Tauber, C., Péran, P., Arlicot, N., Pariente, J., & Payoux, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15613 · Cited by 70
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 71
Astrocytic TSPO upregulation appears before microglial TSPO in Alzheimer’s disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Fraser, B. H., Grégoire, M.-C., Kövari, E., & Millet, P. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200136 · Cited by 65
Lagarde, J., Olivieri, P., Tonietto, M., Tissot, C., Rivals, I., Gervais, P., Caillé, F., Moussion, M., Bottlaender, M., & Sarazin, M. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328623 · Cited by 68
Self-citationDoes inflammation precede tau aggregation in early Alzheimer's disease? A PET study
Parbo, P., Ismail, R., Sommerauer, M., Stokholm, M. G., Hansen, A. K., Hansen, K. V., Amidi, A., Schaldemose, J. L., Gottrup, H., Brændgaard, H., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.004 · Cited by 63
Kim, D. W., Tu, K. J., Wei, A., Lau, A., Gonzalez-Gil, A., Cao, T., Braunstein, K. E., Ling, J. P., Troncoso, J. C., Wong, P. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00589-x · Cited by 71
Brain and Systemic Inflammation in De Novo Parkinson's Disease
Yacoubian, T. A., Fang, Y.-H. D., Gerstenecker, A. T., Amara, A. W., Stover, N. P., Ruffrage, L., Collette, C., Kennedy, R., Zhang, Y., Hong, H., et al. (2023) · Movement Disorders · doi:10.1002/mds.29363 · Cited by 68
Brody, A. L., Hubert, R., Enoki, R., Garcia, L. Y., Mamoun, M. S., Okita, K., London, E. D., Nurmi, E. L., Seaman, L. C., & Mandelkern, M. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.48 · Cited by 67
Wang, Q., Wang, Y., Liu, J., Sutphen, C. L., Cruchaga, C., Blazey, T., Gordon, B. A., Su, Y., Chen, C., Shimony, J. S., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101767 · Cited by 63
Edison, P., & Brooks, D. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179929 · Cited by 65
Wang, M., Tang, G., Zhou, C., Guo, H., Hu, Z., Hu, Q., & Li, G. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110387 · Cited by 62
Widespread microglial activation in multiple system atrophy
Kübler, D., Wächter, T., Cabanel, N., Su, Z., Turkheimer, F. E., Dodel, R., Brooks, D. J., Oertel, W. H., & Gerhard, A. (2019) · Movement Disorders · doi:10.1002/mds.27620 · Cited by 61
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies
Terkelsen, M. H., Klæstrup, I. H., Hvingelby, V. S., Lauritsen, J., Pavese, N., & Romero‐Ramos, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223245 · Cited by 64
Immune mechanisms and shared immune targets in neurodegenerative diseases
Weiner, H. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01046-7 · Cited by 72
Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia
Giorgi, F. S., Biagioni, F., Galgani, A., Pavese, N., Lazzeri, G., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228630 · Cited by 63
Zou, J., Tao, S., Johnson, A. S., Tomljanovic, Z., Polly, K., Klein, J., Razlighi, Q. R., Brickman, A. M., Lee, S., Stern, Y., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.019 · Cited by 55
Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease
Faculty, O. B. O. T. M., Boche, D., Gerhard, A., & Rodriguez-Vieitez, E. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04462-w · Cited by 55
Tournier, B. B., Tsartsalis, S., Rigaud, D., Fossey, C., Cailly, T., Fabis, F., Pham, T., Grégoire, M.-C., Kövari, E., Moulin-Sallanon, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.022 · Cited by 62
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [ 18F ]‐ FEMPA PET Study
Khan, W., Corben, L. A., Bilal, H., Vivash, L. E., Delatycki, M. B., Egan, G. F., & Harding, I. H. (2021) · Movement Disorders · doi:10.1002/mds.28825 · Cited by 54
PET Imaging for Early Detection of Alzheimer’s Disease
Bao, W., Jia, H., Finnema, S. J., Cai, Z., Carson, R. E., & Huang, Y. H. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.03.001 · Cited by 54
TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?
Largeau, B., Dupont, A.-C., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/6592139 · Cited by 55
Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation
Fu, W., Vukojevic, V., Patel, A., Soudy, R., MacTavish, D., Westaway, D. A., Kaur, K., Goncharuk, V. D., & Jhamandas, J. H. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0972-9 · Cited by 52
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 55
Hashiguchi, D., Campos, H. C., Wuo‐Silva, R., Faber, J., da Silva, S. G., Ribeiro, A. A. C. M., Arida, R. M., & Longo, B. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190729 · Cited by 52
Mitochondria and Oxidative Stress as a Link between Alzheimer’s Disease and Diabetes Mellitus
Veselov, I. M., Vinogradova, D. V., Maltsev, A. V., Shevtsov, P. N., Spirkova, E. A., Бачурин, С. О., & Shevtsova, E. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914450 · Cited by 55
Ugolini, F., Lana, D., Nardiello, P., Nosi, D., Pantano, D., Casamenti, F., & Giovannini, M. G. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00372 · Cited by 50
Implications of glial metabolic dysregulation in the pathophysiology of neurodegenerative diseases
Afridi, R., Rahman, M. H., & Suk, K. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105874 · Cited by 53
Tipping points in neurodegeneration
Simons, M., Levin, J., & Dichgans, M. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.031 · Cited by 52
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 52
Fluorescence-activated cell sorting to reveal the cell origin of radioligand binding
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Medina, Z., Fraser, B., Grégoire, M., Kövari, E., & Millet, P. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19860408 · Cited by 52
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases
Rehfeldt, S. C. H., Majolo, F., Goettert, M. I., & Laufer, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249677 · Cited by 47
Behavioral and neuropsychiatric disorders in Alzheimer's disease
Cortés, N., Andrade, V., & Maccioni, R. B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180005 · Cited by 57
Cao, L., Guan, P.-P., Zhang, S.-Q., Yang, Y., Huang, X., & Wang, P. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02327-4 · Cited by 48
Mueller, C., Fang, Y.-H. D., Jones, C. L., McConathy, J., Raman, F., Lapi, S. E., & Younger, J. (2023) · Pain · doi:10.1097/j.pain.0000000000002927 · Cited by 54
García-Lorenzo, D., Lavisse, S., Leroy, C., Wimberley, C., Bodini, B., Rémy, P., Veronese, M., Turkheimer, F., Stankoff, B., & Bottlaender, M. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17692599 · Cited by 52
Self-citationLopez‐Picon, F. R., Snellman, A., Eskola, O., Helin, S., Solin, O. H., Haaparanta‐Solin, M., & Rinne, J. O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197608 · Cited by 49
Ni, R., Mu, L., & Ametamey, S. M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0035-5 · Cited by 50
Hao, Y., Guo, M., Feng, Y., Dong, Q., & Cui, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00058 · Cited by 51
Chauveau, F., Becker, G., & Boutin, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05425-w · Cited by 54
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 52
Ibrahim, W. W., Skalicka‐Woźniak, K., Budzyńska, B., & Sayed, N. S. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110239 · Cited by 47
In Vivo Imaging of Microglia With Multiphoton Microscopy
Hierro‐Bujalance, C., Bacskai, B. J., & García-Alloza, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00218 · Cited by 50
Emerging technologies to study glial cells
Hirbec, H., Déglon, N., Foo, L. C., Goshen, I., Grutzendler, J., Hangen, E., Kreisel, T., Linck, N., Muffat, J., Regio, S., et al. (2020) · Glia · doi:10.1002/glia.23780 · Cited by 51
Brain Exosomes: Friend or Foe in Alzheimer’s Disease?
Kaur, S., Verma, H., Dhiman, M., Tell, G., Gigli, G. L., Janes, F., & Mantha, A. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02547-y · Cited by 45
Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease
Jha, D., Bakker, E. N. T. P., & Kumar, R. K. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15788 · Cited by 48
Peña‐Altamira, E., Petralla, S., Massenzio, F., Virgili, M., Bolognesi, M. L., & Monti, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00175 · Cited by 46
Janssen, B., & Mach, R. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.04.005 · Cited by 44
Simmons, D. A., James, M. L., Belichenko, N. P., Semaan, S., Condon, C., Kuan, J., Shuhendler, A. J., Miao, Z., Chin, F. T., & Longo, F. M. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy202 · Cited by 44
Ni, R., Röjdner, J., Voytenko, L. P., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201344 · Cited by 42
The effect of aged microglia on synaptic impairment and its relevance in neurodegenerative diseases
Triviño, J. J., & von Bernhardi, R. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104982 · Cited by 43
Emerging TSPO-PET Radiotracers for Imaging Neuroinflammation: A Critical Analysis
Cumbers, G. A., Harvey-Latham, E. D., Kassiou, M., Werry, E. L., & Danon, J. J. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.09.007 · Cited by 46
Toppala, S., Ekblad, L. L., Tuisku, J., Helin, S., Johansson, J. J., Laine, H. K., Löyttyniemi, E., Marjamäki, P., Blennow, K., Zetterberg, H., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011612 · Cited by 45
Complex roles for reactive astrocytes in the triple transgenic mouse model of Alzheimer disease
Guillemaud, O., Ceyzériat, K., Saint-Georges, T., Cambon, K., Petit, F., Haim, L. B., Sauvage, M.-A. C.-D., Guillermier, M., Bernier, S., Hérard, A., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.010 · Cited by 40
An emerging role for microglia in stress‐effects on memory
Sanguino‐Gómez, J., Buurstede, J. C., Abiega, O., Fitzsimons, C. P., Lucassen, P. J., Eggen, B. J. L., Lesuis, S. L., Meijer, O. C., & Krugers, H. J. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15188 · Cited by 43
Zhou, Z., Hui, E. S. K., Kranz, G. S., Chang, J. R., de Luca, K. E., Pinto, S. M., Chan, W. W. Y., Yau, S., Chau, B. K. H., Samartzis, D., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101767 · Cited by 48
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 42
Self-citationBridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 41
Albrecht, D. S., Sagare, A., Pachicano, M., Sweeney, M. D., Toga, A., Zlokovic, B., Chui, H., Joe, E., Schneider, L., Morris, J. C., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.01.010 · Cited by 37
Hou, X., Bi, Y., Tan, M., Xu, W., Li, J., Shen, X., Dou, K., Tan, C., Tan, L., & Yu, J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.008 · Cited by 40
The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease
Ghadery, C., Koshimori, Y., Christopher, L., Kim, J., Rusjan, P., Lang, A. E., Houle, S., & Strafella, A. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01714-6 · Cited by 42
Presenilin 1 phosphorylation regulates amyloid-β degradation by microglia
Ledo, J. H., Liebmann, T., Zhang, R., Chang, J. C., Azevedo, E. P., Wong, E., Silva, H. M., Troyanskaya, O. G., Bustos, V., & Greengard, P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0856-8 · Cited by 41
Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease
Bera, A., Lavanya, G., Reshmi, R., Dev, K., & Kumar, R. K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15611 · Cited by 43
SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis
Ouyang, P., Cai, Z., Peng, J., Lin, S., Chen, X., Chen, C., Feng, Z., Wang, L., Song, G.-L., & Zhang, Z. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103064 · Cited by 40
Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia
Kreisl, W. C., Henter, I. D., & Innis, R. B. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.08.004 · Cited by 41
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 40
Bruno, L., Karagil, S., Mahmood, A., Elbediwy, A., Stolinski, M., & Mackenzie, F. E. (2021) · Cells · doi:10.3390/cells10113144 · Cited by 42
Wang, Q., Chen, G., Schindler, S. E., Christensen, J. J., McKay, N. S., Liu, J., Wang, S., Sun, Z., Hassenstab, J. J., Su, Y., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001152 · Cited by 46
Zhang, M., Qian, X., Hu, J., Zhang, Y., Lin, X., Hai, W., Shi, K., Jiang, X., Li, Y., Tang, H., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06446-3 · Cited by 38
Chaney, A. M., Bauer, M., Bochicchio, D., Smigova, A., Kassiou, M., Davies, K. E., Williams, S. R., & Boutin, H. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14251 · Cited by 38
Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment
Knezevic, D., Verhoeff, N. P. L. G., Hafizi, S., Strafella, A. P., Graff‐Guerrero, A., Rajji, T. K., Pollock, B. G., Houle, S., Rusjan, P., & Mizrahi, R. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17741395 · Cited by 38
TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma
Pigeon, H., Pérès, E. A., Truillet, C., Jégo, B., Boumezbeur, F., Caillé, F., Zinnhardt, B., Jacobs, A. H., Bihan, D. L., & Winkeler, A. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz029 · Cited by 36
Oumata, N., Lu, K., Teng, Y., Cavé, C., Yu, P., Galons, H., & Roques, B. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114578 · Cited by 36
Noradrenergic neuromodulation in ageing and disease
Krohn, F., Lancini, E., Ludwig, M., Leiman, M., Guruprasath, G., Haag, L., Panczyszyn, J., Düzel, E., Hämmerer, D., & Betts, M. J. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105311 · Cited by 41
Immune modulation to treat Alzheimer’s disease
Duggan, M. R., Morgan, D., Price, B. R., Rajbanshi, B., Martín‐Peña, A., Tansey, M. G., & Walker, K. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00828-x · Cited by 44
Rodríguez-Chinchilla, T., Quiroga‐Varela, A., Molinet-Dronda, F., Belloso-Iguerategui, A., Merino-Galán, L., Jiménez‐Urbieta, H., Gago, B., & Rodríguez‐Oroz, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04772-4 · Cited by 35
Fu, J., Duan, J., Mo, J., Xiao, H., Huang, Y., Chen, W., Xiang, S., Yang, F., Chen, Y., & Xu, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.624304 · Cited by 36
Rahman, S. O., Singh, R. K., Hussain, S., Akhtar, M., & Najmi, A. K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.040 · Cited by 35
Burfeind, K. G., Zhu, X., Norgard, M. A., Levasseur, P. R., Huisman, C., Michaelis, K. A., Olson, B. G., & Marks, D. L. (2020) · Glia · doi:10.1002/glia.23796 · Cited by 33
Intestinal Flora Affect Alzheimer's Disease by Regulating Endogenous Hormones
Wu, Y., Hang, Z., Tong, L., & Du, H. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03784-w · Cited by 34
Foucault-Fruchard, L., Doméné, A., Page, G., Windsor, M., Emond, P., Rodrigues, N., Dollé, F., Damont, A., Buron, F., Routier, S., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.019 · Cited by 32
Saba, W., Goutal, S., Auvity, S., Kühnast, B., Coulon, C., Kouyoumdjian, V., Buvat, I., Leroy, C., & Tournier, N. (2017) · Addiction Biology · doi:10.1111/adb.12548 · Cited by 35
Self-citationCaruso, G. I., Spampinato, S. F., Costantino, G., Merlo, S., & Sortino, M. A. (2021) · Biomedicines · doi:10.3390/biomedicines9050466 · Cited by 35
Vogrinc, D., Kramberger, M. G., Emeršič, A., Čučnik, S., Goričar, K., & Dolžan, V. (2023) · Antioxidants · doi:10.3390/antiox12020316 · Cited by 38
The microglial translocator protein (TSPO) in Alzheimer’s disease reflects a phagocytic phenotype
Garland, E. F., Antony, H., Kulagowska, L., Scott, T., Rogien, C., Bottlaender, M., Nicoll, J. A. R., & Boche, D. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02822-x · Cited by 31
Self-citationBrody, A. L., Gehlbach, D. L., Garcia, L. Y., Enoki, R., Hoh, C. K., Vera, D. R., Kotta, K. K., London, E. D., Okita, K., Nurmi, E. L., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5077-3 · Cited by 32
Unravelling the glial response in the pathogenesis of Alzheimer's disease
Alibhai, J. D., Diack, A. B., & Manson, J. C. (2018) · The FASEB Journal · doi:10.1096/fj.201801360r · Cited by 31
Guen, Y. L., Philippe, C., Rivière, D., Lemaître, H., Grigis, A., Fischer, C., Dehaene‐Lambertz, G., Mangin, J., & Frouin, V. (2018) · Brain Structure and Function · doi:10.1007/s00429-018-1808-9 · Cited by 31
Singh, R. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200128121920 · Cited by 32
Deri, Y., Clouston, S., DeLorenzo, C., Gardus, J. D., Bartlett, E. A., Santiago‐Michels, S., Bangiyev, L., Kreisl, W. C., Kotov, R., Huang, C., et al. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100287 · Cited by 35
Garland, E. F., Dennett, O., Lau, L. C., Chatelet, D. S., Bottlaender, M., Nicoll, J. A. R., & Boche, D. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02869-9 · Cited by 34
Self-citationApplication of biomarker-derived fluorescent probes for the detection of Alzheimer's disease
Ding, H., Li, Z., Luo, K., Gong, Q., & Tian, X. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117369 · Cited by 30
Metadata
- Authors
- Hamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., Dubois, B., Gervais, P., Colliot, O., Potier, M. C., Bottlaender, M., Sarazin, M., & the Clinical IMABio3 team
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre d'Acquisition et de Traitement des Images (FR)
- F. Hoffmann-La Roche AG (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-15
- Volume
- 139
- Issue
- 4
- Pages
- 1252-1264
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2298656843
- Cited by
- 519
- References
- 41
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 71 · 2023: 59 · 2022: 47 · 2021: 47 · 2020: 51 · 2019: 51 · 2018: 57 · 2017: 39 · 2016: 10
- FWCI
- 28.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 278850)
- Université Paris Descartes
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, microglial activation, translocator protein (TSPO), [18F]DPA-714, neuroinflammation, prodromal Alzheimer's disease, amyloid imaging, Pittsburgh compound B, clinical progression, amyloidosis, gray matter volume, temporoparietal cortex, frontal cortex, cognitive decline
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Fluorine Radioisotopes, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Pyrazoles, Pyrimidines, Cohort Studies, Microglia, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
